News

Filter

Current filters:

Eptifibatide

1 to 9 of 92 results

Sanofi-Aventis’ otamixaban substantially reduced complications of invasive management of acute coronary syndromes

01-09-2009

French drug major Sanofi-Aventis says that its investigational anti-Xa intravenous anticoagulant otamixaban…

Aventis PharmaCardio-vascularEptifibatideEuropeheparinIntegrilinPharmaceuticalSanofi-Aventis

Integrilin disappoints in EARLY ACS study

09-04-2009

US drug major Schering-Plough's Integrilin (eptifibatide) failed to achieve either the primary or secondary…

EptifibatideIntegrilinSchering PloughSchering-Plough

Affimed's antithrombotic Ab completes proof-of-concept trial

11-12-2006

Germany's Affimed, a privately-held biopharmaceutical firm focused on antibody therapeutics, says that…

AbciximabEptifibatideIntegrilinLillyReoPro

Stock Commentary - New York week to Nov 27

04-12-2006

NEW YORK: equities moved marginally higher for the first two days in the reporting week to November 27,…

AmgenAngiomaxbivalirudinEptifibatideheparinIntegrilinSchering PloughSchering-Plough

Millennium's 2nd-qtr losses down to $17.7M

07-08-2006

The USA's Millennium Pharmaceuticals says that its net income for the second quarter of 2006 improved…

bortezomibEptifibatideIntegrilinSchering PloughSchering-PloughVelcade

Millennium's 1st-qtr 2006 loss narrows 43%

15-05-2006

USA-based cardiovascular and anticancer drug specialist Millennium Pharmaceuticals says that its Generally-Accepted…

bortezomibEptifibatideIntegrilinJohnson & JohnsonSchering PloughSchering-PloughVelcade

Stock Commentary - New York week to Feb 6

13-02-2006

NEW YORK: equities saw up and down movements in the reporting, week to February 6, boosted at times…

AllerganAmgenAmylinByettaEpoetin AlfaEpogenEptifibatideExenatide InjectionIntegrilinRocheSchering PloughSchering-PloughWyeth

1 to 9 of 92 results

Back to top